Cancer & Immunotheraphy



With so much activity around cancer vaccines and immunotherapy right now, can you afford to miss out? It is the place where the global market will come together to share the latest in early-stage scientific advancements, present clinical trial data, discuss new formulations of cancer vaccines and assess the future of combination treatments. Make sure that people are aware of the work you are doing to put yourself at the forefront of the industry.






Cancer & Immunotherapy, Wednesday 4 April 2018

Dr Niranjan Sardesai
Cancer & Immunotherapy

Chair’s opening remarks

Beyond Checkpoint Inhibitors

Dr Jay A. Berzofsky
Cancer & Immunotherapy

What’s next after PD1? Next generation checkpoint inhibitors including anti-TGF-beta

  • A deeper look at TGF-beta as a checkpoint inhibitor.
  • What are its effects on tumour growth and other cell types?
  • Synergy with vaccines and PD1 checkpoint inhibitors.
  • Brief look at other novel checkpoints, regulatory cells and cytokines; LAG3, Tim3
Panel discussion

Networking coffee break

Combination Therapy

Dr Roy Baynes
Cancer & Immunotherapy

PD-1 antibodies are transforming cancer therapy both as monotherapies and in combination

  • PD-1 antibody monotherapy indications continue to expand
  • PD-1 antibody has shown potential important activity when combined with:
    • Standard therapies e.g. chemotherapy
    • Targeted therapies e.g. with TKIs
    • Other immune modifying therapies e.g. IDO-1 inhibitors
    • Oncolytic viruses e.g. TVEC
  • Precision medicine will be increasingly important in patient selection
Dr Jun Tang
Cancer & Immunotherapy

A comprehensive analysis of combination studies in immuno-oncology

  • Summary of all IO agents, targets and companies
  • Overview of ongoing PD-1 combination studies
  • Trends and areas to enhance efficiencies
  • Role of Philanthropy in IO
Dr Jun Tang, Senior Research Analyst, Cancer Research Institute
Dr Xiaosong (Susan) Zhang
Cancer & Immunotherapy

Rapid and efficient development of combination therapies through a novel cancer immunotherapy platform.

  • Introduction to Morpheus; a novel cancer immunotherapy platform
  • How to go about selecting a combination study
  • Potential for use across several indications

Networking Lunch & Poster Session

Dr Ching Ching Leow
Cancer & Immunotherapy

CDK4/6 inhibitor abemaciclib enhances efficacy of PD-L1 checkpoint blockade

Cancer Vaccines

Dr Douglas Mcneel
Cancer & Immunotherapy

Synergy of DNA Vaccines with checkpoint inhibitors

  • Selection of appropriate vaccine antigens for prostate cancer
  • Updates from ongoing translational trials of DNA vaccines in prostate cancer
Dr Allan B Dietz
Cancer & Immunotherapy

Hollow microneedles for use in delivery of cancer vaccines

  • Delivery to appropriate target tissue is critical to control the safety and effectiveness of vaccines 
  • We have used a new product developed by 3M to consistently for intradermal delivery of a cellular vaccine 
  • The unit is easy to load and deliver the product 
  • Our autologous DC vaccine using this product has shown evidence of efficacy for newly diagnosed glioblastoma patients.
Dr John Nieland
Cancer & Immunotherapy

The AAVLP platform for prophylactic and therapeutic vaccines with special focus on HPV-L2

  • Adeno Associated Virus Like Particles as a vaccine platform.
  • Broad coverage HPV vaccine without adjuvant, targeting the L2 minor capsid protein.
  • Prophylactic and therapeutic AAVLP-HER2/Neu vaccine.

Networking coffee break

Dr Michael Ciesielski
Cancer & Immunotherapy

Targeting cancer through SurVaxM, a new peptide immunotherapeutic vaccine

  • SurVaxM is a synthetic long peptide (SLP) vaccine with incorporated peptide mimic technology
  • Engineered to trigger a stronger immune response than wild type peptide, through better MHC binding 
  • Completed Phase 1 clinical trial in recurrent glioblastoma
  • Interim phase 2 data and designing a phase 3 trial
  • Exploring other indications and combination therapies
Panel discussion
Cancer & Immunotherapy

Panel Discussion: Tumor neoantigEn SeLection Alliance (TESLA) – discovering the keys to developing personalized cancer vaccines

  • Accurately identifying neo-epitopes
    • What is the diversity of neo-epitope predictions from different groups?
    • How well did these predictions perform in terms of patient sample analysis?
    • Can we identify key parameters that improve the ability to predict neo-epitopes?
  • How do we convert this data into the creation of personalized cancer vaccines?
    • Merits of different vaccines platforms

Chair’s closing remarks and close of congress day 2


Networking Drinks & Party

last published: 02/Apr/18 21:25

Cancer & Immunotherapy, Thursday 5 April 2018

Dr Niranjan Sardesai
Cancer & Immunotherapy

Chair’s opening remarks

Cancer Vaccines Continued

Dr Ildiko Csiki
Cancer & Immunotherapy

DNA vaccines for cancer immunotherapy

  • Introduction to DNA plasmid and electroporation delivery technology
  • Updates in proof of concept studies from various trials
  • Head and neck cancer, bladder cancer, prostate cancer
  • Examples of potential combination partners
  • The regulatory landscape for DNA Vaccines
Dr Mike McCluskie
Cancer & Immunotherapy

Archaeal Lipid Adjuvant Systems for Cancer Vaccine Development

  • Sulfated semi-synthetic archaeal lipids are potent modulators of vaccine immunity
  • A single lipid formulation can effectively deliver cancer antigens and provide protection in cancer models
  • Therapeutic benefit can be extended through combining vaccines and check-point inhibitor blockade


Dr Scot Roberts
Cancer & Immunotherapy

Densigen, a versatile immunotherapeutic platform to promote broad and robust T cell immunity against viral infections and cancer

  • Densigens are rationally designed, CD4+/CD8+ T cell epitope-containing peptides modified by a fluorocarbon moiety providing self-adjuvanting properties
  • Densigen-based immunotherapeutics promote robust T cell responses in humans while achieving broad population coverage
  • Densigens simultaneously target multiple antigenic determinants to prevent immune escape
  • Prime-boost immunizations with Densigens can act synergistically to promote better T cell responses

Networking coffee break

Dr Corey Casper
Cancer & Immunotherapy

Translational Studies Informing the Design and Feasibility of a vaccine against Epstein Barr Virus

  • Opportunities for the development of a vaccine against EBV
  • Understanding the medical necessity, market potential and public health use of EBV Vaccine.
  • The science behind the 3 vaccine candidates that currently exist:
    • Pre-clinical safety data
    • Updates on progress of phase 1 trials.
Dr Eliav Barr
Cancer & Immunotherapy

Advances in the development of a replication-deficient human cytomegalovirus vaccine for the prevention of congenital infection

  • The Burden of Disease caused by maternal/fetal/infant CMV infection
  • Natural History of maternal/fetal/infant CMV infection
  • Merck’s CMV vaccine candidate
  • Strategies to demonstrate the efficacy and safety profiles of CMV vaccines targeted to prevent congenital CMV infection

Networking Lunch & Poster Session


Dr Angela Shen

Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

  • A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease
  • What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders
  • Identifying whether obstacles exist that inhibit the development of beneficial vaccines
  • Recommendations on how best to promote and incentivize vaccine innovation and development
Dr Jeffrey Stoddard

Zoster vaccine recombinant, adjuvanted: A journey from research to approval

  • Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01
  • Sharing positive results from Phase III revaccination study 
Dr Walter A Orenstein

With polio eradication succeeding, should measles eradication come next?

  • Changing the perception from polio: Focusing on measles elimination to build our overall immunization program
  • Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles
  • Surveillance -  a weakness in our system?
  • Cost of controlling outbreaks and the consequences
Dr Paul Offit

Vaccine hesitancy: How to respond to the media to advance better health

  • Challenges to communicating science through the opaque prism of the media
  • How certain cultural biases can influence the perception of science 

3:40 Chair closing remarks and end of congress

last published: 02/Apr/18 21:25


Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071